Scott Gottlieb

A new study has warned that declining childhood vaccination rates in the United States could trigger a dramatic resurgence of diseases that were eradicated years ago. What Happened: On Sunday, former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb shared a study on X...

Former FDA Commissioner Dr. Scott Gottlieb commented on the heated mask debate between Chief Medical Advisor to the President Dr. Anthony Fauci and Republican Sen. Rand Paul, noting "both made valid points." What Paul Argues: During a U.S. Senate hearing on Thursday, Paul accused Fauci of...

The United States has so far rolled out more than 63 million COVID-19 vaccine doses with an average of 1.3 million doses administered per dayy. Continued momentum in the vaccination effort implies the U.S. could return to a form of normalcy within a few months, according to former FDA...

The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower by 1% on Monday morning in part over concerns about a new strain of coronavirus that has reportedly been circulating in the U.K. What Happened? On Saturday, the U.K. implemented strict lockdowns in London and other areas of England in response...

The United Kingdom government's approval of Pfizer Inc.'s (NYSE: PFE) vaccine against the novel coronavirus is "monumental" and will put pressure on U.S. regulators to follow suit, CNBC's Jim Cramer said Wednesday on "Squawk on the Street." 'Let's Get It...

Monday could go down in the history books as "a great day for humanity" after Pfizer Inc. (NYSE: PFE) released encouraging results from its COVID-19 vaccine study, Pfizer CEO Albert Bourla said on CNBC's "Squawk Box." Pfizer's 'Overwhelming' Data: Pfizer's...

U.S. President Donald Trump has a "good chance of doing well" after he and First Lady Melania Trump announced they tested positive for the coronavirus, former FDA Commissioner Dr. Scott Gottlieb — a Trump appointee — said on CNBC's "Squawk Box...

Coronavirus vaccine developer AstraZeneca plc (NYSE: AZN) said Tuesday that a Phase 3 trial being conducted with Oxford University has been put on hold for a safety review. Several experts said they're not overly concerned the development will derail the likelihood of a COVID-19...

The Trump administration is urging individual states to start working on a strategy to distribute a coronavirus vaccine by Nov. 1, but some experts are skeptical of the quick timeline, as it comes just weeks after interim study results. Early Vaccine Data Within Weeks: U.K.-based AstraZeneca plc (...

Media reports of the U.S. Food and Drug Administration looking to approve a coronavirus vaccine prior to the completion of clinical trials appear to be taken out of context, former FDA Commissioner Dr. Scott Gottlieb said on CNBC's "Squawk Box." Emergency Use Authorization: FDA...

The FDA granted emergency authorization of convalescent plasma to treat hospitalized COVID-19 patients on Sunday, and this could be helpful in treating sick people, former FDA  Commissioner Dr. Scott Gottlieb said on CNBC's "Squawk Box." An Important Distinction: It may be...

Johnson & Johnson (NYSE: JNJ) plans on enrolling up to 60,000 people in a coronavirus vaccine trial, likely as part of a global development and regulatory approval strategy, ex-FDA Commissioner Scott Gottlieb said Friday on CNBC's "Squawk Box." J&J's Global Approval...

Global stock markets jumped higher Tuesday morning after Russia became the first country to confirm that a coronavirus vaccine is safe for immediate use. Russia named its vaccine the "Sputnik V" in a reference to the cold war era, when the country was first to launch an artificial Earth...

Therapeutic companies working on a COVID-19 vaccine could earn a profit on their product if it's priced similarly to a standard flu vaccine, former FDA commissioner and Pfizer Inc. (NYSE: PFE) board member Dr. Scott Gottlieb said on CNBC's "Squawk Box." What Happened: It's...

Many investors are working under the assumption that a safe vaccine against the coronavirus will allow society to return to how it was pre-pandemic. Investors may be missing part of the story, including how the vaccines work, former FDA Commissioner Dr. Scott Gottlieb said on CNBC's "...